<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111656</url>
  </required_header>
  <id_info>
    <org_study_id>75/07</org_study_id>
    <nct_id>NCT01111656</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b</brief_title>
  <official_title>SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (&quot;SWABIMS Follow Up-study&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Viollier AG, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PharmaPart</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study&quot;
      is the follow up study of the &quot;SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple
      Sclerosis (SWABIMS)&quot; (see http://www.clinicaltrials.gov. Identifier: NCT00942591) SWABIMS
      evaluated the efficacy, safety and tolerability of atorvastatin 40 mg in addition to
      interferon-beta 1b compared to interferon-beta 1b monotherapy in patients with
      relapsing-remitting multiple sclerosis for 15 month. The SWABIMS Follow up study observes
      patients that finish the SWABIMS study for another 12 month with ongoing unchanged
      medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Multiple sclerosis is a chronic inflammatory autoimmune disease of the central nervous
      system. Statins are lipid-lowering drugs which inhibit the
      3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA-) reductase, which is the main regulatory
      enzyme of cholesterol biosynthesis. In recent years many studies have demonstrated, that
      statins have anti-inflammatory and immunomodulatory properties in addition to their
      lipid-lowering effects. Therefore, statins may have therapeutic potential in immune-mediated
      disorders such as multiple sclerosis. Studies in experimental allergic encephalomyelitis
      (EAE), the animal model for the human demyelinating disease multiple sclerosis, as well as
      smaller studies in patients with relapsing-remitting multiple sclerosis showed beneficial
      effect on the course of the disease. But there are also reports of negative impact of statins
      on multiple sclerosis. Therefore, bigger studies are needed to investigate the therapeutical
      potential of statins in multiple sclerosis.

      Objective

      To assess the efficacy, safety and tolerability of the combination of atorvastatin 40mg p.o.
      daily and interferon-beta 1b sc e.o.d compared to monotherapy with interferon-beta-1b sc
      e.o.d in patients with relapsing-remitting multiple sclerosis for 12 month after completing
      the SWABIMS study.

      Methods

      Multi-center, rater-blinded, parallel-group, two arm, randomized study. Patients with
      relapsing-remitting forms of MS, respecting all inclusion/exclusion criteria, were randomized
      in the SWABIMS study in two equal-size parallel arms after three months of treatment with
      interferon-beta 1b, receiving atorvastatin 40mg/d or not in addition to interferon-beta 1b
      for 12 month.

      After successful completion of the study, patients were asked to participate in the &quot;SWABIMS
      Follow up study&quot; for another 12 month with ongoing medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with new lesions on T2-weighted images after 12 months of treatment</measure>
    <time_frame>Month 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with new lesions on T2-weighted images after 12 months of treatment</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gd-enhancing lesions on T1-weighted images after 12 months of treatment.</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total T2-hyperintense lesion volume (burden of disease, BOD) after 12 months of treatment.</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical atrophy (changes in brain volume, changes in grey matter and white matter) on magnetic resonance imaging (MRI) after 12 months of treatment</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical disease progression (Expanded Disability Status Scale [EDSS], Multiple Sclerosis Functional Composite [MSFC] )</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional systems scores (of Expanded Disability Status Scale [EDSS] and Multiple Sclerosis Functional Composite [MSFC] )</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapse-free patients after 12 months of treatment</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate after 12 months of treatment</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gd-enhancing lesions on T1-weighted images after 12 months of treatment.</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total T2-hyperintense lesion volume (burden of disease, BOD) after 12 months of treatment.</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical atrophy (changes in brain volume, changes in grey matter and white matter) on magnetic resonance imaging (MRI)after 12 months of treatment</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical disease progression (Expanded Disability Status Scale [EDSS] , Multiple Sclerosis Functional Composite [MSFC] )</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional systems scores (of Expanded Disability Status Scale [EDSS] and Multiple Sclerosis Functional Composite [MSFC] )</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapse-free patients after 12 months of treatment</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate after 12 months of treatment</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of first relapse</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon beta-1b 250ug subcutaneously every other day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1b group</intervention_name>
    <description>Patients receive interferon beta-1b 250ug subcutaneously every other day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1b/Atorvastatin group</intervention_name>
    <description>Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successful completion of the SWABIMS study

          -  Written informed consent

        Exclusion Criteria

          -  Any disease other than multiple sclerosis that would better explain the patient's
             signs and symptoms

          -  Secondary progressive MS

          -  Uncontrolled severe medical disorder

          -  Participation in any other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinrich Mattle, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Neurology, Bern University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Bern University Hospital, and University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Kamm CP, Mattle HP; SWABIMS Study Group. SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. Trials. 2009 Dec 14;10:115. doi: 10.1186/1745-6215-10-115.</citation>
    <PMID>20003436</PMID>
  </reference>
  <reference>
    <citation>Youssef S, St√ºve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002 Nov 7;420(6911):78-84.</citation>
    <PMID>12422218</PMID>
  </reference>
  <reference>
    <citation>Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000 Dec;6(12):1399-402.</citation>
    <PMID>11100127</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. H. Mattle</name_title>
    <organization>Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland</organization>
  </responsible_party>
  <keyword>Multi-center</keyword>
  <keyword>randomized</keyword>
  <keyword>prospective</keyword>
  <keyword>parallel-group</keyword>
  <keyword>rater-blinded</keyword>
  <keyword>RR-MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

